As with many other industries, there is a prevailing belief that the 21st Century will be the Asian Century when it comes to drug development and the pharmaceutical industry. Already, markets such as China are predicted to overtake the US to become the largest pharmaceutical market in the world during the first half of this century. As the globalization of clinical research gathers pace, the Asian region will continue to grow making it the most exciting frontier for biotechnology and pharmaceutical companies to conduct clinical research in. In a recent Novotech survey of executives from biopharmaceutical companies, 98% of respondents said they would consider the Asia Pacific region for future clinical trials.
Home to 60% of the world’s population, Asia’s popularity for clinical research and development has been fueled by four key factors:
- 1. Cost-effectiveness and time efficiencies afforded by large populations, significant numbers of treatment naïve patients and high urban densities
- 2. A wide range of chronic and lifestyle disease patterns driven by rising prosperity and aging populations
- 3. Increasingly robust and efficient regulatory and ethics processes
- 4. Quality improvements resulting from massive investments in research infrastructure and human resources
Access to Patients
In the last two decades, the total universe of clinical trials has not only greatly increased in number but become far more complex. The twin factors of increasing volume and greater complexity are at least as important as cost considerations when assessing the Asian century in the context of the clinical trials. Far more people, and far more patients, live in Asia than any other continent. Combined with a relatively low base of clinical trials historically in the region, it is not difficult to see why Asia is of such importance to the pharmaceutical industry. Led predominantly by US-based biotechnology companies, the region is now also increasingly popular for biotechnology sponsored phase II and III clinical trials. This trend is likely to gather momentum, with the key being greater access to patients. In many therapeutic areas, the patient demographics and disease prevalence is comparable across the world, and this weighs heavily on the decision where to conduct larger pivotal studies. The factors influencing such decisions are largely the same for both pharmaceutical and biotechnology companies.
With the widespread adoption of the international Good Clinical Practice guidelines around the world, regulatory hurdles around data acceptability for clinical trials conducted in emerging markets have been steadily coming down. Indeed a recent report by the European Medicines Agency (EMA) indicated that more than a quarter of all patients enrolled in pivotal trials that were submitted to the Agency during the period 2005-2011 came from the rest of the world (ROW) represented predominantly by Asia and Latin America. Of greater interest is that this trend is increasing. So, whilst only 20% of all patients came from ROW in 2005, this number had risen to 37% in 2011 (Ref. Clinical trials Submitted in Marketing Authorization Applications to the European Medicines Agency – April 2013)
Infrastructure and Government Support:
Fueled by the continued interest, governments in Asian countries increasingly view biomedical/life sciences industry as a key segment for future economic growth. Substantial financial support has been granted to this segment resulting in improved clinical research infrastructure in many of the region’s countries. Another important reason for Asia’s growing demand is the availability of world class medical professionals and investigators. Economic and political factors, such as trade agreements between countries, also have an impact on easing trial registration and timelines, thus affecting trial numbers. For example, Japan, South Korea, and the People’s Republic of China have established a tripartite partnership, with a common regulatory body in the works, in recognition of their ethnic, genetic, and economic similarities. However, as attractive as the Asia may be, navigating the maze of trial logistics, local regulations and cultural differences can present major challenges. To conduct clinical research in Asia, it is therefore very important to work with a partner with local expertise and capabilities on the ground.
Dr. John Moller, Chief Operating Officer - Asia, Novotech
Dr. John Moller, Chief Operating Officer – Asia, Novotech
A qualified physician, John has in-depth knowledge of the health services sector and is adept at developing innovative strategies, and achieving complex business outcomes quickly. Prior to joining Novotech, John was Managing Director of IVF Australia and a Director of the parent company Virtus Health. The business employed over 400 staff and included a number of day hospitals and advanced diagnostics laboratories.
John was previously a management consultant with the Boston Consulting Group and Partners in Performance specialising in supporting private equity transactions and implementing growth and operational improvement initiatives.
In addition to his medical qualifications, John also holds a Masters of Business Administration degree from University of Oxford (UK) and a Bachelor of Arts (Advanced Logic) from University of Canterbury (New Zealand).Message Presenter
Kim Wong, Head of Regulatory Affairs, Novotech
Kim Wong, Head of Regulatory Affairs, Novotech
Kim Wong heads the Regulatory Affairs function at Novotech, where she oversees Novotech’s regulatory affairs consulting services, including planning, management and preparation of registration applications on behalf of clients to regulatory authorities. She is also responsible for oversight, planning, preparation and review of ethics committee and regulatory authority submissions for clinical trial approval.
Kim has been with Novotech for over 13 years and has a broad scope of knowledge across many facets of clinical research, drug development, pharmacovigilance and regulatory affairs. Kim holds a Medical Science degree from the University of Sydney.Message Presenter
Chayanontchaimongkol Boonchaliew, Clinical Operations Manager - Thailand, Novotech
Chayanontchaimongkol Boonchaliew, Clinical Operations Manager – Thailand, Novotech
Chayanont provides management oversight and leadership to a team of experienced SCRAs, CRA and other support staff. He works closely with the feasibility team and ensures that clinical trials are conducted according to all applicable Good Clinical Practice (GCP) guidelines, regulatory requirements, Standard Operating Procedures (SOPs) and the project agreement.
Chayanont brings more than 18 years of clinical experience to the role, joining Novotech in 2014. He has previously held senior positions at regional and global CRO and Pharmaceutical companies.
Chayanont holds a Master’s of Science degree (Clinical Pharmacology) and Bachelor of Pharmacy degree from Chiang Mai University, Thailand.Message Presenter
Who Should Attend?
- Senior Clinical Development/Clinical Operations Personnel
- Heads of R&D
- Outsourcing Executives
From biotechnology and pharmaceutical companies
Established in 1996, Novotech is the largest independent CRO in Australia. With operations in Australia & New Zealand, China, Hong Kong, India, Malaysia, the Philippines, Singapore, South Africa, South Korea, Taiwan and Thailand, Novotech’s service offering has come to be recognized for its quality both by our clients, as well as industry analyst groups evident from being awarded the “CRO Best Practice Award” for the third time in recent years by Frost and Sullivan. The demand for global clinical outsourcing services continues to grow at a rapid pace, with Asia providing the new frontier. Headquartered in Australia, Novotech is the ideal gateway for expansion of clinical programs into the region.
Our comprehensive range of services extends the full spectrum of clinical drug development needs. Our Australian Head Office is situated in Sydney, with regional offices in Melbourne and Brisbane providing easy access to the most important population centres in Australia. Supported by regional staff across the country and in New Zealand, our coverage of the Australia/New Zealand region is second to none.
With Asian services launched in 2007, Novotech’s operations provide access to the most dynamic and fast growing clinical research hubs in the region.
Our company philosophy is focussed on hiring experienced professionals with local environment expertise. Both in Australia and internationally, the company boasts some of the most experienced full time Project Managers and CRAs in the markets it operates. Our vision is to be recognised as the CRO of choice by all our clients in the Asia Pacific, something that we are well on the way to achieving.
In addition, through key external partnerships and strategic alliances we offer worldwide reach to our clients, including the USA, Canada and Europe. This combination of a relatively small, flexible CRO, coupled with the ability to confidently manage very large projects allows us to move a project from initial planning stage to recruitment with dramatic speed.
We have developed excellent relationship with key opinion leaders (KOLs) having been managing clinical trials for over 19 years. On average, Novotech staff have relationships with 85% of the top 50 investigators and 90% of the top 20 sites in each of its countries. Novotech Sydney is ISO 9001 certified and is regularly audited not only by clients, but external quality endorsement organisations as part of maintaining ISO credentials.